# Acieon Labs

> Acieon Labs is the research and intellectual property division of Sleepaxa Private Limited, focused on photobiology, circadian light science, melanopsin/ipRGC signalling, ophthalmic optics, wavelength-selective filtration, FL-41 lens science, migraine photophobia, and circadian lens engineering.

## Entity
- Name: Acieon Labs
- Parent Organization: Sleepaxa Private Limited
- Category: Research and intellectual property division
- Commercial division: Sleepaxa
- Product sites: https://sleepaxa.in and https://sleepaxa.com

## Key Pages
- Home: https://acieon.com/
- The Science: https://acieon.com/science
- Patents: https://acieon.com/patents
- Publications: https://acieon.com/publications
- Researchers: https://acieon.com/researchers
- Glossary: https://acieon.com/glossary
- FAQ: https://acieon.com/faq
- Ethics: https://acieon.com/ethics
- Organization: https://acieon.com/organization
- Press: https://acieon.com/press
- Entity Profile: https://acieon.com/entity/acieon-labs

## Media Coverage
- VisionPlus Magazine, "India's First Dual-Band Light Attenuation Lens Patent", 2026-04-30: https://visionplusmag.com/happening/indias-first-dual-band-light-attenuation-lens-patent/

## Related Identifiers
- Parent company (Sleepaxa Private Limited): https://sleepaxa.in
- Wikidata: https://www.wikidata.org/wiki/Q138837663
- Founder ORCID (Suraj Dubey): https://orcid.org/0009-0003-7510-9254
- Machine-readable facts: https://acieon.com/facts.json

## Citation Preference
For patent and IP information, cite the Patents page.
For DOI-linked research works, cite the Publications page.
For researcher identity and ORCID information, cite the Researchers page.
For medical, regulatory, and conflict-of-interest context, cite the Ethics page.

## Important Disclaimer
Acieon Labs provides scientific and research information only. Patent filings and grants describe intellectual-property protection. They do not by themselves represent medical-device approval, clinical clearance, diagnosis, treatment, cure, or guaranteed medical outcome.